MSFP
ARQT icon

Mark Sheptoff Financial Planning’s Arcutis Biotherapeutics ARQT Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.87K Hold
300
– – ﹤0.01% 391
2026
Q1 		$7.03K Hold
300
– – ﹤0.01% 385
2025
Q4 		$8.71K Buy
+300
New +$7.68K ﹤0.01% 363

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mark Sheptoff Financial Planning's ARQT Position: Q2 2026 in Review

Mark Sheptoff Financial Planning held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 300 shares worth $7.87K. The position accounts for ﹤0.01% of the portfolio, ranked #391.

Mark Sheptoff Financial Planning first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.71K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Mark Sheptoff Financial Planning held 300 shares of Arcutis Biotherapeutics worth $7.87K as of Q2 2026.
  • Mark Sheptoff Financial Planning left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Mark Sheptoff Financial Planning's portfolio in Q2 2026, its #391 holding.
  • Mark Sheptoff Financial Planning first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mark Sheptoff Financial Planning's Arcutis Biotherapeutics position peaked at $8.71K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2026, filed 13 Aug 2026.